v3.25.2
Fair value measurement - Contingent Consideration (Details)
$ in Thousands, € in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Jun. 30, 2025
EUR (€)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration $ 15,931   $ 10,860  
Changes in fair value of contingent consideration 3,470 $ (1,621)    
Current portion of contingent consideration 0   0  
Contingent consideration $ 15,900   10,900  
One hundred percent likelihood of AMT-260 advancing into clinical development        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Percentage of increase in Probability of Success 100.00%      
Changes in fair value of contingent consideration $ 51,400      
uniQure France [S.A.S]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration 15,931   $ 10,860  
Changes in fair value of contingent consideration 3,470      
uniQure France [S.A.S] | Maximum        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration payable upon achievement of contractually defined milestones $ 168,000     € 143.1
Contingent consideration discount rate percentage 14.40%   16.20%  
uniQure France [S.A.S] | Minimum        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration discount rate percentage 13.80%   15.30%